Browse drugs

…und Sodium glucose co-transporter-2 inhibitors (SGLT2i) such as canagliflozin have been shown to have beneficial cardiovascular and renal eff…

…ple with T2DM and established CVD to receive either the SGLT2i, empagliflozin, or placebo.5 To be eligible for this study, people had to meet…

…several T2DM drugs (metformin, rosiglitazone, canagliflozin and sitagliptin) on mouse and human ovarian cancer cells in vitro, and the effe…

…=111,357; e.g., empagliflozin, dapagliflozin, canagliflozin) or DPP4is (n=43,868; e.g., sitagliptin, linagliptin) without cross-exposu…

…ltiple risk factors for cardiovascular disease, irrespective of metformin use.14–19Despite the demonstrated benefits of SGLT2i and GLP-1R…

…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …

… kidney disease progression by 24% [HR 0.76; 95% CI 0.67–0.87]. Canagliflozin reduced the composite renal outcome [HR 0.66; 95% CI 0.53–0.81]…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…